Global Blood Therapeutics Annual Revenue, Number of Employees, Growth and Funding

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:2012
Lead Investor(s):Cantor Fitzgerald & Co.
Press

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Global Blood Therapeutics's estimated annual revenue is currently $24M per year.
  • Global Blood Therapeutics received $115.0M in venture funding in December 2017.
  • Global Blood Therapeutics's estimated revenue per employee is $82,560

Employee Data

  • Global Blood Therapeutics has 291 Employees.
  • Global Blood Therapeutics grew their employee count by 60% last year.
  • Global Blood Therapeutics currently has 28 job openings.

Executive Contacts

NameTitle
Martine KrausVice President, Regulatory Affairs
Gwendolyn WhitneyVP, US Commercial Operations
Ted LovePresident & CEO
Hing ShamSenior Vice President at Global Blood Therapeutics
Xiang WangAssociate Director
Sarah ThayerExecutive Director, Clinical Operations at Global Blood Therapeutics
Margaret TondaSenior Director
Ze CongSenior Director, Health Economics and Outcomes Research
Mabel ChauDirector, Program Management
David GaoSenior Director, CMC Analytical

Global Blood Therapeutics (GBT) (NASDAQ: GBT), based in South SF, is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. We aim to make a significant impact by treating the root cause or making a meaningful difference in the standards of care. Through in-licensing and continued research and development, were committed to Hope+Science+Community. You can view our social community guidelines at http://www.gbt.com/about/social-community-guidelines/

keywords:Biotechnology,Healthcare,Pharmaceuticals

291

Number of Employees

$24M

Revenue (est)

28

Current Jobs

60%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.2M4310%N/A
Mission Bio
$10.7M7445%N/A
Rigel Pharmaceu...
$42M2904%N/A
ProTrials Resea...
$26.4M1823%N/A
Trace Genomics
$5.9M4137%N/A
Advanced Cell D...
$25.7M1788%N/A
CellMax Life
$5.7M4011%N/A
Vaxart
$4.2M33-15%N/A
Full Spectrum A...
$6M425%N/A
Calysta
$7.1M49-2%N/A

Global Blood Therapeutics News

09/09/2019 - Global Blood Therapeutics: Stock Responds To Voxelotor ...

Global Blood Therapeutics is preparing to “go-it-alone” in commercialization. I provide my three reasons why the company can handle the ...

09/05/2019 - GBT Announces US Food and Drug Administration ...

05, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug ...

09/05/2019 - Why Global Blood Therapeutics Stock Jumped 10.9% Today

After disclosing that the Food and Drug Administration has accepted the company's application to review its lead product candidate for approval ...

Global Blood Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-01-07$48.0MBMultipleArticle
2016-06-21$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2016-06-27$112.3MUndisclosedJ.P. Morgan Securities LLCArticle
2017-02-23$125.0MUndisclosedCantor Fitzgerald & CoArticle
2017-03-01$143.8MUndisclosedCantor Fitzgerald & CoArticle
2017-12-18$115.0MUndisclosedCantor Fitzgerald & Co.Article

Global Blood Therapeutics Executive Hires

DateNameTitleReference
2014-06-18Ted W. LoveCEOArticle
2014-08-05Hing ShamSVP ChemistryArticle
2015-04-15Jung E. ChoiChief Business/Strategy OfficerArticle
2016-04-05Jeffrey FarrowCFOArticle
2016-10-13Tricia SuvariChief Legal OfficerArticle
2018-03-07David JohnsonChief Commercial OfficerArticle
2018-08-22Heidi L WagnerSVP Government Affairs and PolicyArticle